CLEARPOINT NEURO INC
CLPTNASDAQTrading Snapshot
- Day Range
- $819.45 – $835.77
- 52-Week Range
- $8.27 – $30.10
- Volume
- $3.54B
- Avg Volume
- $2.36B
- Shares Outstanding
- 30.0M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $37M
- Last Q Revenue
- $11M
- P/E Ratio
- —
- P/S Ratio
- 11.0x
- EPS (TTM)
- $-1.18
- Dividend Yield
- —
- Dilution (1yr)
- +4.8%
Why Investors Own CLPT
- ✓High-growth profile — revenue up +39.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CLEARPOINT NEURO INC
CLPT
StockOtter · stockotter.spaceAbout CLEARPOINT NEURO INC
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
CLEARPOINT NEURO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CLPT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CLEARPOINT NEURO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.